Skip to main content

Research Repository

Advanced Search

All Outputs (5)

?-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: A propensity score-matched cohort study (2021)
Journal Article
Nakafero, G., Grainge, M. J., Valdes, A. M., Townsend, N., D. Mallen, C., Zhang, W., …Abhishek, A. (2021). β-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: A propensity score-matched cohort study. Rheumatology, 60(12), 5686-5696. https://doi.org/10.1093/rheumatology/keab234

Objectives: To examine the association between ?-blocker prescription and first primary-care consultation for knee OA, hip OA, knee pain and hip pain. Methods: Data source: Clinical Practice Research Datalink. Participants aged ?40 years in receipt o... Read More about ?-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: A propensity score-matched cohort study.

Analgesic effects of the cathepsin K inhibitor L-006235 in the monosodium iodoacetate model of osteoarthritis pain (2018)
Journal Article
Nwosu, L. N., Gowler, P. R., Burston, J. J., Rizoska, B., Tunblad, K., Lindström, E., …Chapman, V. (2018). Analgesic effects of the cathepsin K inhibitor L-006235 in the monosodium iodoacetate model of osteoarthritis pain. PAIN Reports, 3(6), Article 685. https://doi.org/10.1097/PR9.0000000000000685

© 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain. Introduction: The mounting evidence that osteoclasts play an important role in osteoarthritis (OA) pain lead us to invest... Read More about Analgesic effects of the cathepsin K inhibitor L-006235 in the monosodium iodoacetate model of osteoarthritis pain.

Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply (2018)
Journal Article
Persson, M. S., Sarmanova, A., Doherty, M., & Zhang, W. (2018). Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply. Rheumatology, 57(11), 2060–2061. https://doi.org/10.1093/rheumatology/key269

MD reports a grant from AstraZeneca funding a non-drug PI-led study in Nottingham (Sons of Gout study) and honoraria for Advisory boards on osteoarthritis and gout for AstraZeneca, Grunenthal, Mallinckrodt, and Roche, outside the submitted work. WZ r... Read More about Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply.

Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials (2018)
Journal Article
Persson, M. S., Sarmanova, A., Doherty, M., & Zhang, W. (2018). Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials. Rheumatology, 57(10), 1830-1837. https://doi.org/10.1093/rheumatology/key131

Objectives The role of inflammation in OA is controversial and it is unclear whether suppressing inflammation with conventional or biologic DMARDs is effective. A systematic review and meta-analysis of randomized controlled trials (RCTs) was condu... Read More about Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials.